# IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

> **NCT03474263** · PHASE2 · WITHDRAWN · sponsor: **Implicit Bioscience**

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Biologic: IC14 (monoclonal antibody against human CD14)

## Key facts

- **NCT ID:** NCT03474263
- **Lead sponsor:** Implicit Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-07-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No enrollment
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474263, "IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03474263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*